Literature DB >> 33490068

The Identification of Plasma Exosomal miR-423-3p as a Potential Predictive Biomarker for Prostate Cancer Castration-Resistance Development by Plasma Exosomal miRNA Sequencing.

Tianyu Guo1,2, Yang Wang1,3, Jing Jia4, Xueying Mao1, Elzbieta Stankiewicz1, Glenda Scandura1, Edwina Burke1, Lei Xu1,5, Jacek Marzec1,6, Caitlin R Davies1, Jiaying Jasmin Lu1, Prabhakar Rajan1,7,8,9, Alistair Grey7,8, Karen Tipples7, John Hines7,9, Sakunthala Kudahetti1, Tim Oliver1, Thomas Powles1, Constantine Alifrangis7,9, Manish Kohli10,11, Greg Shaw7,8,9, Wen Wang12, Ninghan Feng3, Jonathan Shamash13, Daniel Berney1, Liang Wang4, Yong-Jie Lu1,3.   

Abstract

Castration-resistant prostate cancer (CRPC) is the major cause of death from prostate cancer. Biomarkers to improve early detection and prediction of CRPC especially using non-invasive liquid biopsies could improve outcomes. Therefore, we investigated the plasma exosomal miRNAs associated with CRPC and their potential for development into non-invasive early detection biomarkers for resistance to treatment. RNA-sequencing, which generated approximately five million reads per patient, was performed to identify differentially expressed plasma exosomal miRNAs in 24 treatment-naive prostate cancer and 24 CRPC patients. RT-qPCR was used to confirm the differential expressions of six exosomal miRNAs, miR-423-3p, miR-320a, miR-99a-5p, miR-320d, miR-320b, and miR-150-5p (p = 7.3 × 10-8, 0.0020, 0.018, 0.0028, 0.0013, and 0.0058, respectively) firstly in a validation cohort of 108 treatment-naive prostate cancer and 42 CRPC patients. The most significant differentially expressed miRNA, miR-423-3p, was shown to be associated with CRPC with area under the ROC curve (AUC) = 0.784. Combining miR-423-3p with prostate-specific antigen (PSA) enhanced the prediction of CRPC (AUC = 0.908). A separate research center validation with 30 treatment-naive and 30 CRPC patients also confirmed the differential expression of miR-423-3p (p = 0.016). Finally, plasma exosomal miR-423-3p expression in CRPC patients was compared to 36 non-CRPC patients under androgen depletion therapy, which showed significantly higher expression in CRPC than treated non-CRPC patients (p < 0.0001) with AUC = 0.879 to predict CRPC with no difference between treatment-naive and treated non-CRPC patients. Therefore, our findings demonstrate that a number of plasma exosomal miRNAs are associated with CRPC and miR-423-3p may serve as a biomarker for early detection/prediction of castration-resistance.
Copyright © 2021 Guo, Wang, Jia, Mao, Stankiewicz, Scandura, Burke, Xu, Marzec, Davies, Lu, Rajan, Grey, Tipples, Hines, Kudahetti, Oliver, Powles, Alifrangis, Kohli, Shaw, Wang, Feng, Shamash, Berney, Wang and Lu.

Entities:  

Keywords:  biomarker; castration-resistance development; miR-423-3p; plasma exosome miRNA; prostate cancer

Year:  2021        PMID: 33490068      PMCID: PMC7817948          DOI: 10.3389/fcell.2020.602493

Source DB:  PubMed          Journal:  Front Cell Dev Biol        ISSN: 2296-634X


  50 in total

1.  A specific miRNA signature in the peripheral blood of glioblastoma patients.

Authors:  Patrick Roth; Jörg Wischhusen; Caroline Happold; P Anoop Chandran; Silvia Hofer; Günter Eisele; Michael Weller; Andreas Keller
Journal:  J Neurochem       Date:  2011-06-17       Impact factor: 5.372

2.  Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.

Authors:  Charles J Ryan; Matthew R Smith; Karim Fizazi; Fred Saad; Peter F A Mulders; Cora N Sternberg; Kurt Miller; Christopher J Logothetis; Neal D Shore; Eric J Small; Joan Carles; Thomas W Flaig; Mary-Ellen Taplin; Celestia S Higano; Paul de Souza; Johann S de Bono; Thomas W Griffin; Peter De Porre; Margaret K Yu; Youn C Park; Jinhui Li; Thian Kheoh; Vahid Naini; Arturo Molina; Dana E Rathkopf
Journal:  Lancet Oncol       Date:  2015-01-16       Impact factor: 41.316

3.  limma powers differential expression analyses for RNA-sequencing and microarray studies.

Authors:  Matthew E Ritchie; Belinda Phipson; Di Wu; Yifang Hu; Charity W Law; Wei Shi; Gordon K Smyth
Journal:  Nucleic Acids Res       Date:  2015-01-20       Impact factor: 16.971

4.  Shifting paradigms in the estimation of survival for castration-resistant prostate cancer: A tertiary academic center experience.

Authors:  Mehran Afshar; Felicity Evison; Nicholas D James; Prashant Patel
Journal:  Urol Oncol       Date:  2015-06-06       Impact factor: 3.498

5.  Exosomal miRNAs: Biological Properties and Therapeutic Potential.

Authors:  Guoku Hu; Kristen M Drescher; Xian-Ming Chen
Journal:  Front Genet       Date:  2012-04-20       Impact factor: 4.599

6.  DIANA-miRPath v3.0: deciphering microRNA function with experimental support.

Authors:  Ioannis S Vlachos; Konstantinos Zagganas; Maria D Paraskevopoulou; Georgios Georgakilas; Dimitra Karagkouni; Thanasis Vergoulis; Theodore Dalamagas; Artemis G Hatzigeorgiou
Journal:  Nucleic Acids Res       Date:  2015-05-14       Impact factor: 16.971

7.  Plasma extracellular RNA profiles in healthy and cancer patients.

Authors:  Tiezheng Yuan; Xiaoyi Huang; Mark Woodcock; Meijun Du; Rachel Dittmar; Yuan Wang; Susan Tsai; Manish Kohli; Lisa Boardman; Tushar Patel; Liang Wang
Journal:  Sci Rep       Date:  2016-01-20       Impact factor: 4.379

Review 8.  The Hippo Pathway in Prostate Cancer.

Authors:  Omar Salem; Carsten G Hansen
Journal:  Cells       Date:  2019-04-23       Impact factor: 6.600

9.  Deregulation of miR-100, miR-99a and miR-199b in tissues and plasma coexists with increased expression of mTOR kinase in endometrioid endometrial carcinoma.

Authors:  Anna Torres; Kamil Torres; Anna Pesci; Marcello Ceccaroni; Tomasz Paszkowski; Paola Cassandrini; Giuseppe Zamboni; Ryszard Maciejewski
Journal:  BMC Cancer       Date:  2012-08-24       Impact factor: 4.430

10.  Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases.

Authors:  Eberhard Varenhorst; Rami Klaff; Anders Berglund; Per Olov Hedlund; Gabriel Sandblom
Journal:  Cancer Med       Date:  2016-01-14       Impact factor: 4.452

View more
  9 in total

Review 1.  Extracellular vesicles and particles impact the systemic landscape of cancer.

Authors:  Serena Lucotti; Candia M Kenific; Haiying Zhang; David Lyden
Journal:  EMBO J       Date:  2022-09-02       Impact factor: 14.012

Review 2.  The Potential Role of Exosomal Proteins in Prostate Cancer.

Authors:  Shangzhi Feng; Kecheng Lou; Xiaofeng Zou; Junrong Zou; Guoxi Zhang
Journal:  Front Oncol       Date:  2022-06-07       Impact factor: 5.738

Review 3.  Diagnostic and prognostic significance of extracellular vesicles in prostate cancer drug resistance: A systematic review of the literature.

Authors:  Anna Maria Grimaldi; Marco Salvatore; Carlo Cavaliere
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-03-09       Impact factor: 5.455

4.  miR-423-3p activates FAK signaling pathway to drive EMT process and tumor growth in lung adenocarcinoma through targeting CYBRD1.

Authors:  Jun Ma; Wuhao Huang; Chaonan Zhu; Xiaoyan Sun; Qiang Zhang; Lianmin Zhang; Qi Qi; Xiaoming Bai; Yun Feng; Changli Wang
Journal:  J Clin Lab Anal       Date:  2021-10-29       Impact factor: 2.352

Review 5.  Liquid biopsy: Exosomal microRNAs as novel diagnostic and prognostic biomarkers in cancer.

Authors:  K Auxzilia Preethi; Sushmaa Chandralekha Selvakumar; Kehinde Ross; Selvaraj Jayaraman; Deusdedit Tusubira; Durairaj Sekar
Journal:  Mol Cancer       Date:  2022-02-16       Impact factor: 27.401

Review 6.  Molecular mechanisms and clinical applications of exosomes in prostate cancer.

Authors:  Xiaolin Cui; Qiang Fu; Xueying Wang; Pengcheng Xia; Xianglun Cui; Xiaohui Bai; Zhiming Lu
Journal:  Biomark Res       Date:  2022-07-29

Review 7.  Molecular Biomarkers in Cancer.

Authors:  Virinder Kaur Sarhadi; Gemma Armengol
Journal:  Biomolecules       Date:  2022-07-23

Review 8.  Advances in the Current Understanding of the Mechanisms Governing the Acquisition of Castration-Resistant Prostate Cancer.

Authors:  Yifeng Mao; Gaowei Yang; Yingbang Li; Guowu Liang; Wangwang Xu; Mingqiu Hu
Journal:  Cancers (Basel)       Date:  2022-07-31       Impact factor: 6.575

Review 9.  Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges.

Authors:  Blanca Trujillo; Anjui Wu; Daniel Wetterskog; Gerhardt Attard
Journal:  Br J Cancer       Date:  2022-06-17       Impact factor: 9.075

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.